A recent study indicates that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Research printed in a prominent health publication shows that while overweight people often shed substantial amounts of their body weight while using the jabs, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"Users using these treatments need to be aware of the danger of rapid rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment mass within about one and a half years.
Analyzing Therapies
The analysis, which reviewed 37 of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with other pills.
Scientists emphasize that individuals who lose weight through diet and exercise typically experience a less rapid weight regain—around 0.1 kg a month—post-intervention.
Understanding the Quick Rebound
Nutrition scientists propose the way of the jabs explains the amplified regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations far above than normal may cause the system to produce less of its own natural GLP-1, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' means appetite is uncontrolled, making overeating a significant risk."
An Ongoing Disease?
Medical guidelines recommend the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals argue that, given the significant potential of weight regain, the therapy is often long-term.
This perspective is reinforced by pharmaceutical companies, who say that the results "underscore the chronic nature of excess weight," comparing it to managing conditions like diabetes.
User Accounts
Users who have come off the medication report a powerful return of appetite.
"It was like something flipping and you're instantly ravenous," described an individual.
This challenge is worsened if users have not adopted sustainable lifestyle or habit modifications during therapy.
Widespread Adoption
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among women compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, researchers stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and lasting health benefits likely depends on ongoing lifestyle management.
